Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
20 nov. 2023 10h00 HE
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
15 nov. 2023 07h30 HE
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
08 nov. 2023 08h45 HE
|
AIM ImmunoTech Inc.
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over...
Mendus presenterar uppdaterad data från ALISON-studien med vididencel i äggstockscancer vid SITC 2023
06 nov. 2023 02h00 HE
|
Mendus AB
Pressmeddelande Stockholm, 6 november 2023 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag publiceringen av uppdaterade...
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
06 nov. 2023 02h00 HE
|
Mendus AB
Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
01 nov. 2023 14h54 HE
|
The Wistar Institute
PHILADELPHIA, PA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith...
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
23 oct. 2023 08h00 HE
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
Non-Invasive Cancer Diagnostics Market Size & Share Surpass USD 207 billion by 2031, Growing at a CAGR of 7.0% - Exclusive Study by Transparency Market Research
19 oct. 2023 11h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global non-invasive cancer diagnostics market is projected to flourish at a CAGR of 7.0%...
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 sept. 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
11 sept. 2023 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...